JP7262100B2 - 長期寛容を誘導するためのおよびアテローム性動脈硬化症におけるマクロファージ蓄積を解決するための自然免疫システムの標的化 - Google Patents

長期寛容を誘導するためのおよびアテローム性動脈硬化症におけるマクロファージ蓄積を解決するための自然免疫システムの標的化 Download PDF

Info

Publication number
JP7262100B2
JP7262100B2 JP2018556339A JP2018556339A JP7262100B2 JP 7262100 B2 JP7262100 B2 JP 7262100B2 JP 2018556339 A JP2018556339 A JP 2018556339A JP 2018556339 A JP2018556339 A JP 2018556339A JP 7262100 B2 JP7262100 B2 JP 7262100B2
Authority
JP
Japan
Prior art keywords
hdl
mtor
tissue
traf6i
nanoparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018556339A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019515926A (ja
JP2019515926A5 (https=
Inventor
ムルダー，ウィレム
オチャンド，ジョーディ
ファヤド，ザヒ
ブラザ，ムーニア
デゥイベンブーアデン，ラファエル
フェイ，フランソワ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Icahn School of Medicine at Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School of Medicine at Mount Sinai filed Critical Icahn School of Medicine at Mount Sinai
Publication of JP2019515926A publication Critical patent/JP2019515926A/ja
Publication of JP2019515926A5 publication Critical patent/JP2019515926A5/ja
Priority to JP2023060872A priority Critical patent/JP2023085437A/ja
Application granted granted Critical
Publication of JP7262100B2 publication Critical patent/JP7262100B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1224—Lipoprotein vesicles, e.g. HDL and LDL proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1275—Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018556339A 2016-04-29 2017-05-01 長期寛容を誘導するためのおよびアテローム性動脈硬化症におけるマクロファージ蓄積を解決するための自然免疫システムの標的化 Active JP7262100B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023060872A JP2023085437A (ja) 2016-04-29 2023-04-04 長期寛容を誘導するためのおよびアテローム性動脈硬化症におけるマクロファージ蓄積を解決するための自然免疫システムの標的化

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662329676P 2016-04-29 2016-04-29
US62/329,676 2016-04-29
PCT/US2017/030444 WO2017190145A1 (en) 2016-04-29 2017-05-01 Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023060872A Division JP2023085437A (ja) 2016-04-29 2023-04-04 長期寛容を誘導するためのおよびアテローム性動脈硬化症におけるマクロファージ蓄積を解決するための自然免疫システムの標的化

Publications (3)

Publication Number Publication Date
JP2019515926A JP2019515926A (ja) 2019-06-13
JP2019515926A5 JP2019515926A5 (https=) 2020-06-18
JP7262100B2 true JP7262100B2 (ja) 2023-04-21

Family

ID=60161161

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018556339A Active JP7262100B2 (ja) 2016-04-29 2017-05-01 長期寛容を誘導するためのおよびアテローム性動脈硬化症におけるマクロファージ蓄積を解決するための自然免疫システムの標的化
JP2023060872A Pending JP2023085437A (ja) 2016-04-29 2023-04-04 長期寛容を誘導するためのおよびアテローム性動脈硬化症におけるマクロファージ蓄積を解決するための自然免疫システムの標的化

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023060872A Pending JP2023085437A (ja) 2016-04-29 2023-04-04 長期寛容を誘導するためのおよびアテローム性動脈硬化症におけるマクロファージ蓄積を解決するための自然免疫システムの標的化

Country Status (11)

Country Link
US (2) US20190290593A1 (https=)
EP (2) EP4014967A1 (https=)
JP (2) JP7262100B2 (https=)
CN (2) CN109640959B (https=)
AU (3) AU2017257189B2 (https=)
CA (1) CA3021645A1 (https=)
DK (1) DK3448364T3 (https=)
ES (1) ES2913073T3 (https=)
PL (1) PL3448364T3 (https=)
PT (1) PT3448364T (https=)
WO (1) WO2017190145A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023085437A (ja) * 2016-04-29 2023-06-20 アイカーン スクール オブ メディスン アット マウント サイナイ 長期寛容を誘導するためのおよびアテローム性動脈硬化症におけるマクロファージ蓄積を解決するための自然免疫システムの標的化

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018370237B2 (en) * 2017-11-20 2024-10-17 Icahn School Of Medicine At Mount Sinai Inhibiting trained immunity with a therapeutic nanobilogic composition
US20230001010A1 (en) * 2019-07-19 2023-01-05 The Regents Of The University Of Michigan Compositions and methods for treating autoimmune disorders
US20220409702A1 (en) * 2019-11-22 2022-12-29 The Research Foundation For The State University Of New York Compositions and methods for use in type 1 diabetes
CN111494320A (zh) * 2020-04-24 2020-08-07 上海交通大学医学院附属仁济医院 一种载糖皮质激素的纳米载体及其制备和应用
KR20230030644A (ko) * 2020-06-29 2023-03-06 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 항-단백질 단일-도메인 항체 및 이를 포함하는 폴리펩타이드
AU2022239614A1 (en) * 2021-03-19 2023-10-12 Icahn School Of Medicine At Mount Sinai Compounds for regulating trained immunity, and their methods of use
CN114788835B (zh) * 2022-04-07 2024-01-23 中山大学附属第三医院 Foxp3阳性巨噬细胞在制备治疗急性脑梗死药物中的应用
WO2025240555A1 (en) * 2024-05-14 2025-11-20 The Regents Of The University Of Michigan Nanoparticle compositions associated with celastrol and/or rapamycin

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130252879A1 (en) 2010-10-26 2013-09-26 Industry-Academic Cooperation Foundation, Yeungnam University Rapamycin formulation using recombinant high-density lipoprotein including apolipoprotein a-i and a mutant thereof

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1138436A (en) 1978-02-24 1982-12-28 Gerhard Baschang Process for the manufacture of novel antigens
JPS5528933A (en) 1978-08-21 1980-02-29 Dai Ichi Seiyaku Co Ltd Muramyldipeptide dimer
JPS5618996A (en) 1979-06-21 1981-02-23 Dai Ichi Seiyaku Co Ltd Muramyldipeptide derivative
FI75578C (fi) 1979-07-25 1988-07-11 Ciba Geigy Ag Analogifoerfarande foer framstaellning av farmakologiskt verkande lipofila fosfatidylmuramylpeptider.
JPS58172399A (ja) 1982-04-05 1983-10-11 Dai Ichi Seiyaku Co Ltd ムラミルトリペプチド誘導体
EP0102319B1 (de) 1982-07-23 1987-08-19 Ciba-Geigy Ag Verwendung von Muramylpeptiden oder deren Analogen zur Prophylaxe und Therapie von Virusinfektionen
FI852105L (fi) 1984-05-29 1985-11-30 Ciba Geigy Ag Acylerade sockerderivat, foerfarande foer deras framstaellning och deras anvaendning.
JPS6157597A (ja) 1984-08-29 1986-03-24 Toshiyuki Hamaoka ムラミルペプチド活性エステル誘導体
EP0192609A3 (de) 1985-02-20 1988-04-27 Ciba-Geigy Ag Acylierte Hexosederivate und Verfahren zu ihrer Herstellung
EP0192611A3 (de) 1985-02-20 1988-05-11 Ciba-Geigy Ag Acylierte Hexosederivate und Verfahren zu ihrer Herstellung
US4640911A (en) 1985-05-29 1987-02-03 Ciba-Geigy Corporation Acylated sugar derivatives, processes for their manufacture, and their use
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5506204A (en) 1991-11-19 1996-04-09 Peptech (Uk) Limited Muramyl compounds for treatment of septic shock
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5349060A (en) 1993-01-07 1994-09-20 American Home Products Corporation Rapamycin 31-ester with N,N-dimethylglycine derivatives useful as immunosuppressive agents
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
GB9320820D0 (en) 1993-10-08 1993-12-01 Biokine Tech Ltd Compounds for medicinal use
SK78196A3 (en) 1993-12-17 1997-02-05 Sandoz Ag Rapamycin demethoxy-derivatives, preparation method thereof and pharmaceutical agent containing them
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
GB9413935D0 (en) 1994-07-11 1994-08-31 Peptech Uk Ltd Use of maramyl peptide compounds
GB9419011D0 (en) 1994-09-21 1994-11-09 Peptech Uk Ltd Use of muramyl peptide compounds
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5985890A (en) 1995-06-09 1999-11-16 Novartis Ag Rapamycin derivatives
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
GB9618673D0 (en) 1996-09-06 1996-10-16 Peptech Uk Ltd The use of muramyl peptides
CA2407897A1 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
CA2319928A1 (en) 2000-09-18 2002-03-18 Vasogen Ireland Limited Apoptosis-mimicking synthetic entities and use thereof in medical treatments
GB0025414D0 (en) 2000-10-16 2000-11-29 Consejo Superior Investigacion Nanoparticles
US7592008B2 (en) 2000-11-20 2009-09-22 The Board Of Trustees Of The University Of Illinois, A Body Corporate And Politic Of The State Of Illinois Membrane scaffold proteins
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
AU2004224761A1 (en) 2003-03-26 2004-10-07 Cytos Biotechnology Ag HIV-peptide-carrier-conjugates
MXPA06006738A (es) 2003-12-19 2006-08-31 Univ North Carolina Metodos para fabricar micro- y nano-estructuras aisladas utilizando litografia suave o de impresion.
JP4224115B2 (ja) 2004-04-14 2009-02-12 ワイス ラパマイシン４２−エステル誘導体の位置特異的合成
KR100560102B1 (ko) 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
WO2006080951A2 (en) 2004-07-01 2006-08-03 Yale University Targeted and high density drug loaded polymeric materials
CA2587411A1 (en) 2004-11-17 2006-05-26 Protiva Biotherapeutics, Inc. Sirna silencing of apolipoprotein b
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
JP2009504192A (ja) 2005-08-19 2009-02-05 サイリーン ファーマシューティカルズ インコーポレーティッド ヒトリボソームＤＮＡ（ｒＤＮＡ）およびリボソームＲＮＡ（ｒＲＮＡ）核酸ならびにそれらの使用
CA2683063A1 (en) 2007-04-09 2008-10-16 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
CN101096386A (zh) 2007-06-05 2008-01-02 复旦大学 Dectin-1与热休克蛋白Hsp60聚合物及其编码核酸和应用
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
US7928100B2 (en) 2007-10-05 2011-04-19 Cylene Pharmaceuticals, Inc. Quinolone analogs and methods related thereto
JP2011500569A (ja) 2007-10-12 2011-01-06 マサチューセッツ インスティテュート オブ テクノロジー ワクチンナノテクノロジー
EP2217221B1 (en) 2007-10-17 2018-06-27 Korea Advanced Institute of Science and Technology Ldl-like cationic nanoparticles for deliverying nucleic acid gene, method for preparing thereof and method for deliverying nucleic acid gene using the same
CN105903029A (zh) 2007-12-12 2016-08-31 大学健康网络 高密度脂蛋白样肽磷脂支架（“hpps”）纳米颗粒
WO2009106999A2 (en) 2008-02-28 2009-09-03 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Hollow nanoparticles and uses thereof
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
US8268796B2 (en) 2008-06-27 2012-09-18 Children's Hospital & Research Center At Oakland Lipophilic nucleic acid delivery vehicle and methods of use thereof
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
CN102264364B (zh) 2008-10-22 2014-06-18 康奈尔大学 一种多环化合物及其相关方法
US20120015899A1 (en) 2008-10-25 2012-01-19 Plant Bioscience, Limited Modified plant virus particles and uses therefor
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
US9051567B2 (en) 2009-06-15 2015-06-09 Tekmira Pharmaceuticals Corporation Methods for increasing efficacy of lipid formulated siRNA
US10525152B2 (en) 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
WO2011159877A2 (en) 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
EP2620156B1 (en) 2010-08-23 2019-03-27 Kang Stem Biotech Co., Ltd. Pharmaceutical composition for preventing or treating immune diseases or inflammatory diseases, containing stem cells treated with nod2 agonist or cultured product thereof
US20140086839A1 (en) 2011-03-17 2014-03-27 Tel Hashomer Medical Research Infrastructure And Services Ltd. Quinolone analogs for treating autoimmune diseases
CN102178954B (zh) 2011-04-25 2014-05-28 中国药科大学 具有血管壁靶向和逆向转运胆固醇功能的重组高密度脂蛋白载药系统及其应用
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
WO2013192310A1 (en) * 2012-06-19 2013-12-27 Massachusetts Institute Of Technology Mass production and size control of nanoparticles through controlled microvortices
EP2703384A1 (en) 2012-08-27 2014-03-05 Ludwig-Maximilians-Universität München Inhibitors of CD40-TRAF6 interaction
IL292510A (en) 2013-11-05 2022-06-01 Cognate Bioservices Inc Combinations of checkpoint inhibitors and therapeutics to treat cancer
CN103589699B (zh) 2013-11-05 2015-05-13 江南大学 一种可溶性淀粉底物特异性提高的环糊精糖基转移酶
ES2754207T3 (es) 2013-11-28 2020-04-16 Tel Hashomer Medical Res Infrastructure & Services Ltd Inhibidores de la ARN polimerasa I y usos de los mismos
PL4023249T3 (pl) 2014-04-23 2025-03-10 Modernatx, Inc. Szczepionki z kwasem nukleinowym
WO2016019333A1 (en) 2014-07-31 2016-02-04 Kinemed, Inc. The effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties
US10610564B2 (en) 2015-02-26 2020-04-07 Stc.Unm IRGM and precision autophagy controls for antimicrobial and inflammatory disease states and methods of detection of autophagy
US11642419B2 (en) 2015-03-25 2023-05-09 The Regents Of The University Of Michigan Compositions and methods for treating cardiovascular related disorders
JP2018516847A (ja) 2015-03-25 2018-06-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 生体高分子薬を送達するための組成物及び方法
WO2016155809A1 (en) 2015-03-31 2016-10-06 Biontech Rna Pharmaceuticals Gmbh Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell
ES2819473T3 (es) 2015-04-20 2021-04-16 Memorial Sloan Kettering Cancer Center Obtención de imágenes de macrófagos asociados a tumor
WO2016172615A1 (en) 2015-04-24 2016-10-27 University Of Delaware Synthetic n-acetyl-muramic acid derivatives and uses thereof
US10995140B2 (en) 2015-06-05 2021-05-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. GM-CSF/CD40L vaccine and checkpoint inhibitor combination therapy
BR112018000217A2 (pt) 2015-07-15 2018-09-04 Celator Pharmaceuticals Inc sistemas de distribuição de nanopartículas aperfeiçoados
US20180221289A1 (en) 2015-08-06 2018-08-09 Autotelic Llc Phospholipid-cholesteryl ester nanoformulations and related methods
CA3008837A1 (en) * 2015-12-18 2017-06-22 Northwestern University Nitric oxide releasing high density lipoprotein-like nanoparticles (no hdl nps)
US20190008918A1 (en) 2016-03-08 2019-01-10 Bioxcel Corporation Immunomodulation therapies for cancer
CN109640959B (zh) 2016-04-29 2023-03-17 西奈山伊坎医学院 靶向先天免疫系统以诱导长期耐受性及解决动脉粥样硬化中的巨噬细胞累积
EP3464270B1 (en) 2016-05-24 2022-02-23 Genentech, Inc. Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
WO2018071549A1 (en) 2016-10-11 2018-04-19 New York University Nanoparticles and uses thereof
CN106831614B (zh) 2017-01-09 2020-07-28 清华大学 取代的苯并二氮杂环类化合物及其制备方法和用途
WO2018187515A1 (en) 2017-04-04 2018-10-11 Avidea Technologies, Inc. Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
AU2018370237B2 (en) 2017-11-20 2024-10-17 Icahn School Of Medicine At Mount Sinai Inhibiting trained immunity with a therapeutic nanobilogic composition
EP3713548A4 (en) 2017-11-21 2021-06-23 Icahn School of Medicine at Mount Sinai Promoting trained immunity with therapeutic nanobiologic compositions
KR102198900B1 (ko) 2019-05-10 2021-01-07 서강대학교 산학협력단 질병 치료용 나노입자 복합체 및 이의 제조방법
AU2022239614A1 (en) 2021-03-19 2023-10-12 Icahn School Of Medicine At Mount Sinai Compounds for regulating trained immunity, and their methods of use
JP2025511149A (ja) 2022-03-31 2025-04-15 アイカーン スクール オブ メディスン アット マウント サイナイ 免疫調節のためのスフィンゴ脂質をロードしたナノ生物製剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130252879A1 (en) 2010-10-26 2013-09-26 Industry-Academic Cooperation Foundation, Yeungnam University Rapamycin formulation using recombinant high-density lipoprotein including apolipoprotein a-i and a mutant thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Proc. Intl. Soc. Mag. Reson. Med.，2014年，Vol. 22，p. 2821

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023085437A (ja) * 2016-04-29 2023-06-20 アイカーン スクール オブ メディスン アット マウント サイナイ 長期寛容を誘導するためのおよびアテローム性動脈硬化症におけるマクロファージ蓄積を解決するための自然免疫システムの標的化

Also Published As

Publication number Publication date
EP4014967A1 (en) 2022-06-22
US20190290593A1 (en) 2019-09-26
CA3021645A1 (en) 2017-11-02
JP2019515926A (ja) 2019-06-13
DK3448364T3 (da) 2022-05-02
AU2017257189A1 (en) 2018-11-15
CN109640959A (zh) 2019-04-16
AU2025217324A1 (en) 2025-09-04
US20230218537A1 (en) 2023-07-13
CN109640959B (zh) 2023-03-17
AU2017257189B2 (en) 2022-03-31
WO2017190145A1 (en) 2017-11-02
PL3448364T3 (pl) 2022-08-16
PT3448364T (pt) 2022-05-04
EP3448364A4 (en) 2019-12-25
JP2023085437A (ja) 2023-06-20
US12377054B2 (en) 2025-08-05
ES2913073T3 (es) 2022-05-31
EP3448364A1 (en) 2019-03-06
AU2022204675B2 (en) 2025-09-04
AU2022204675A1 (en) 2022-09-15
CN116077439A (zh) 2023-05-09
EP3448364B1 (en) 2022-02-09

Similar Documents

Publication Publication Date Title
US12377054B2 (en) Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
EP3490605B1 (en) Replacement of cytotoxic preconditioning before cellular immunotherapy
US20180064662A1 (en) Novel compositions and uses of metformin agents
JP7796707B2 (ja) 治療用ナノバイオロジー組成物での訓練された免疫の阻害
JP2020502094A (ja) 免疫応答を調節するためのオキサビシクロヘプタン
US8303952B2 (en) Methods for inducing in vivo tolerance
WO2016180781A1 (en) Combination therapy of mesothelioma
EP3836951A1 (en) Peptides and compositions for targeted treatment and imaging
KR20240158980A (ko) 유기 화합물
AU2024208037B2 (en) Medicinal products and methods for the alleviation of cancer immunotherapy-associated cytokine release syndrome
HK40093107A (zh) 靶向先天免疫系统以诱导长期耐受性及解决动脉粥样硬化中的巨噬细胞累积
JP6878418B2 (ja) 移植片拒絶反応の処置方法
US20210322508A1 (en) Peptides and compositions for targeted treatment and imaging
EA043659B1 (ru) Иммуноаблативные виды терапии
HK40008076A (en) Replacement of cytotoxic preconditioning before cellular immunotherapy
HK40008076B (en) Replacement of cytotoxic preconditioning before cellular immunotherapy
Von Rossum Regulation of T Cell Death in Alloimmune-Mediated Vascular Rejection

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200427

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220427

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220801

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230307

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230404

R150 Certificate of patent or registration of utility model

Ref document number: 7262100

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250